Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-2151
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
mRNA-2151 is an investigational, multiplexed mRNA-based T-cell engager (TCE) therapeutic developed by Moderna for the treatment of solid tumors, specifically ovarian cancer. Delivered via lipid nanoparticles (LNPs), mRNA-2151 encodes two distinct T-cell engagers targeting two undisclosed, clinically validated tumor-associated antigens (TAAs) (providing Signal 1) along with a co-stimulatory molecule (providing Signal 2). This multiplexed approach is designed to enhance anti-tumor efficacy, improve T-cell fitness, and overcome the highly immunosuppressive tumor microenvironment characteristic of ovarian cancer. The program is in preclinical development, with Phase 1 clinical trials planned to initiate in 2027.
02
Targets
CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on mRNA-2151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-2151.